成都先导股东深圳钧天拟减持1006.78万股 占总股本2.51%

Core Viewpoint - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. announced that shareholder Shenzhen Jun Tian Investment Enterprise (Limited Partnership) plans to reduce its stake by 10,067,751 shares, accounting for 2.51% of the total share capital, within three months through centralized bidding and block trading [1][3]. Shareholder and Holding Situation - As of the announcement date, Shenzhen Jun Tian holds 10,067,751 shares, representing 2.51% of the company, acquired before the IPO. It is not a controlling shareholder or a significant stakeholder [2]. - Jun Tian's action partner, Jun Tian Venture Capital Co., Ltd., holds 0 shares, maintaining the combined holding at 2.51% [2]. Details of the Reduction Plan - The reduction will occur from January 22, 2026, to April 21, 2026, with a total of 10,067,751 shares to be sold [3]. - Shenzhen Jun Tian has received approval from the China Securities Investment Fund Industry Association and complies with relevant regulations regarding the reduction of shares [3]. - The reduction must adhere to specific rules, such as not exceeding 2% of the total shares within a 30-day period through block trading [3]. Historical Reduction Situation - In the past 12 months, Shenzhen Jun Tian reduced its holdings by 1,859,413 shares (0.46% of total shares) between August 28, 2025, and November 3, 2025, at prices ranging from 24.01 to 30.05 yuan per share [4].